Skip to main navigation Contact Us About Us Pipeline Technology Clinical Trials Investors Careers You are here: Home / Investors / Press Releases Investor Relations Investors Press Releases Events & Presentations Corporate Governance Corporate Responsibility Financials & Filings Analyst Coverage Stock Information Investor FAQs Contact Us Email Alerts Tools Shareholder Tools Print Share Press Releases Year: - Any - Items per page 10 DATE TITLE AND SUMMARY ADDITIONAL FORMATS Toggle Summary Nov 21, 2021 Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor View HTML PDF Version Toggle Summary Nov 19, 2021 Xencor to Present at Upcoming Investor Conferences View HTML PDF Version Toggle Summary Nov 12, 2021 Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting View HTML PDF Version Toggle Summary Nov 12, 2021 Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting View HTML PDF Version Toggle Summary Nov 08, 2021 Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 View HTML PDF Version Toggle Summary Nov 04, 2021 Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting View HTML PDF Version Toggle Summary Nov 03, 2021 Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium View HTML PDF Version Toggle Summary Nov 02, 2021 Xencor to Present at Upcoming Investor Conferences View HTML PDF Version Toggle Summary Nov 01, 2021 Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021 View HTML PDF Version Toggle Summary Oct 04, 2021 Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies View HTML PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last Displaying 1 - 10 of 316 results Xencor © Copyright 2021 | Privacy Policy